Results 31 to 40 of about 8,366 (155)

A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring bla_KPC-14 Isolated in New York City

mSphere, 2020
Ceftazidime-avibactam is a potent antibiotic combination against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae. Here, we describe a unique ceftazidime-avibactam-resistant and carbapenem-susceptible K.
Siqiang Niu, Kalyan D. Chavda, Jie Wei, Chunhong Zou, Steven H. Marshall, Puneet Dhawan, Deqiang Wang, Robert A. Bonomo, Barry N. Kreiswirth, Liang Chen   +9 more
doaj   +3 more sources

In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–2019

Brazilian Journal of Infectious Diseases, 2021
The Antimicrobial Testing Leadership and Surveillance (ATLAS) global surveillance program collected clinical isolates of Enterobacterales (n = 8416) and Pseudomonas aeruginosa (n = 2521) from 41 medical centers in 10 Latin American countries from 2017 to
James A. Karlowsky, Krystyna M. Kazmierczak, Maria Lavínea Novis de Figueiredo Valente, Elkin Lemos Luengas, Monique Baudrit, Alvaro Quintana, Paurus Irani, Gregory G. Stone, Daniel F. Sahm   +8 more
doaj   +1 more source

Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature

Antibiotics, 2023
Bone and joint infections (BJIs) caused by multidrug-resistant gram-negative bacteria are becoming a concern due to limited therapeutic options. Although not approved for these indications, an ever-growing amount of evidence supports the efficacy and ...
Alessandro Mancuso, Luca Pipitò, Raffaella Rubino, Salvatore Antonino Distefano, Donatella Mangione, Antonio Cascio   +5 more
doaj   +1 more source

Outbreak of Klebsiella pneumoniae ST11 Resistant To Ceftazidime-Avibactam Producing KPC-31 and the Novel Variant KPC-115 during COVID-19 Pandemic in Argentina

Microbiology Spectrum, 2022
We describe an outbreak of Klebsiella pneumoniae sequence type 11 (ST11) producing KPC variants resistant to ceftazidime-avibactam. Six patients hospitalized in the intensive care unit (mostly due to critical COVID pneumonia) presented infection or ...
Federico Nicola, Daniela Cejas, Francisco González-Espinosa, Silvia Relloso, Fabián Herrera, Pablo Bonvehí, Jorgelina Smayevsky, Roque Figueroa-Espinosa, Gabriel Gutkind, Marcela Radice   +9 more
doaj   +1 more source

Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo

BMC Microbiology, 2023
Abstract Background Ceftazidime-avibactam (CZA) improves treatment outcomes for infections caused by carbapenem-resistant organisms, but has led to serious bacterial resistance. Acetylcysteine (NAC) is an approved medication that protects the respiratory tract through antioxidant and anti-inflammatory effects.
Zeyu Huang, Yijia Han, Xiaotuan Zhang, Yao Sun, Yuzhan Lin, Luozhu Feng, Tieli Zhou, Zhongyong Wang   +7 more
openaire   +3 more sources

Ceftazidime/Avibactam: Who Says You Can’t Teach an Old Drug New Tricks?

Journal of Pharmacy & Pharmaceutical Sciences, 2016
Purpose: Gram-negative resistance continues to rise with treatment options becoming more limited. Ceftazidime/avibactam was recently approved in the United States and Europe, which combines an established third-generation cephalosporin with a new, unique,
Katie E. Barber, Jessica K. Ortwine, Ronda L Akins   +2 more
doaj   +1 more source

Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies

Microbiology Spectrum, 2022
The evolution of bacterial antibiotic resistance is exhausting the list of currently used antibiotics and endangers those in the pipeline. The combination of antibiotics is a promising strategy that may suppress resistance development and/or achieve ...
Congjuan Xu, Xiaoya Wei, Yongxin Jin, Fang Bai, Zhihui Cheng, Shuiping Chen, Xiaolei Pan, Weihui Wu   +7 more
doaj   +1 more source

Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing Klebsiella pneumoniae From Patients Without Ceftazidime-Avibactam Use History – A Multicenter Study in China [PDF]

Frontiers in Microbiology, 2020
KPC-producing Klebsiella pneumoniae (KPC-KP) is the most widely spread carbapenem-resistant Enterobacteriaceae (CRE) in China. Avibactam is a novel non-β-lactam β-lactamase inhibitor which is highly active against KPC. Recently, ceftazidime-avibactam (CAZ-AVI) was approved for clinical treatment in China.
Xiaoyan Cui, Bin Shan, Xue Zhang, Fen Qu, Fen Qu, Wei Jia, Bin Huang, Hua Yu, Yi-Wei Tang, Yi-Wei Tang, Yi-Wei Tang, Liang Chen, Liang Chen, Hong Du   +13 more
openaire   +3 more sources

In vitro antibacterial activity of ceftazidime/avibactam in combination against planktonic and biofilm carbapenemase-producing Klebsiella pneumoniae isolated from blood

Journal of Global Antimicrobial Resistance, 2020
Objectives: The aim of this study was to report on in vitro tests of antibacterial activity of ceftazidime/avibactam in combination against planktonic or biofilm KPC carbapenemase-producing Klebsiella pneumoniae (KPC-Kp), the rate of KPC-Kp blood ...
Chiara Papalini, Samuele Sabbatini, Claudia Monari, Antonella Mencacci, Daniela Francisci, Stefano Perito, Maria Bruna Pasticci   +6 more
doaj   +1 more source

Multiple Novel Ceftazidime-Avibactam-Resistant Variants of blaKPC-2-Positive Klebsiella pneumoniae in Two Patients

Microbiology Spectrum, 2022
As the first-line antimicrobial agent for the infection caused by carbapenem-resistant Enterobacterales, ceftazidime-avibactam develops drug resistance during its ever-growing clinical use.
Qingyu Shi, Renru Han, Yan Guo, Yang Yang, Shi Wu, Li Ding, Rong Zhang, Dandan Yin, Fupin Hu   +8 more
doaj   +1 more source